论文部分内容阅读
目的观察骁悉治疗难治性肾病综合征的临床疗效。方法将50例患者随机分为治疗组、对照组,各25例。两组患者均进行一般治疗,对照组在一般治疗基础上加用来氟米特片治疗,治疗组在一般治疗基础上加用骁悉治疗。对24h尿白蛋白、血浆白蛋白、肾功能、血脂及不良反应等项目进行观察并加以分析。结果两组临床总有效率为88%和64%,治疗组总疗效高于对照组(P<0.05);两组24h尿蛋白含量、血浆白蛋白、血肌酐、血尿素氮比较,差异有统计学意义(P<0.05);总胆固醇、三酰甘油比较,差异无统计学意义(P>0.05)。两组不良反应发生率分别为24%和44%,差异无统计学意义(P>0.05)。结论骁悉治疗难治性肾病综合征疗效确切,具有临床实用价值。
Objective To observe the clinical efficacy of Xiaoxitian in the treatment of refractory nephrotic syndrome. Methods 50 patients were randomly divided into treatment group, control group, 25 cases each. Two groups of patients were treated in general, the control group on the basis of general treatment plus leflunomide tablets treatment, the treatment group based on the general treatment plus Xiao Zixin treatment. 24h urinary albumin, serum albumin, renal function, blood lipids and adverse reactions were observed and analyzed. Results The total clinical effective rate was 88% and 64% in both groups, and the total curative effect in the treatment group was higher than that in the control group (P <0.05). There was statistic difference between the two groups in urinary protein content, serum albumin, serum creatinine and blood urea nitrogen (P <0.05). There was no significant difference between total cholesterol and triglyceride (P> 0.05). Adverse reactions in both groups were 24% and 44%, respectively, with no significant difference (P> 0.05). Conclusion The treatment of refractory nephrotic syndrome is effective and has clinical value.